Cargando…

Neuroprotective effect of masitinib in rats with postischemic stroke

This study evaluated the therapeutic potential of masitinib, an oral tyrosine kinase inhibitor with activity against c-Kit and platelet-derived growth factor receptors (PDGFR), to reduce ischemic brain area and neurological deficit. Using a well-established filament model of ischemic stroke in rats,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kocic, Ivan, Kowianski, Przemyslaw, Rusiecka, Izabela, Lietzau, Grazyna, Mansfield, Colin, Moussy, Alain, Hermine, Olivier, Dubreuil, Patrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284372/ https://www.ncbi.nlm.nih.gov/pubmed/25344204 http://dx.doi.org/10.1007/s00210-014-1061-6

Ejemplares similares

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
por: Vermersch, Patrick, et al.
Publicado: (2012)

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
por: Humbert, Martine, et al.
Publicado: (2010)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
por: Mora, Jesus S., et al.
Publicado: (2021)

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
por: Tebib, Jacques, et al.
Publicado: (2009)

The Effect of Simvastatin on the Dynamics of NF-κB-Regulated Neurodegenerative and Neuroprotective Processes in the Acute Phase of Ischemic Stroke
por: Lietzau, Grazyna, et al.
Publicado: (2023)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy
por: Moura, Daniela Silva, et al.
Publicado: (2011)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
por: Davidescu, Lavinia, et al.
Publicado: (2022)

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
por: Deplanque, G., et al.
Publicado: (2015)

Neurovascular Unit as a Source of Ischemic Stroke Biomarkers—Limitations of Experimental Studies and Perspectives for Clinical Application
por: Steliga, Aleksandra, et al.
Publicado: (2019)

Cholesterol as a modifying agent of the neurovascular unit structure and function under physiological and pathological conditions
por: Czuba, Ewelina, et al.
Publicado: (2017)

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats
por: Belin-Rauscent, A., et al.
Publicado: (2018)

Tyrosine Kinase Inhibitors as a New Therapy for Ischemic Stroke and other Neurologic Diseases: Is there any Hope for a Better Outcome?
por: Gągało, Iwona, et al.
Publicado: (2015)

More than Addiction—The Nucleus Accumbens Contribution to Development of Mental Disorders and Neurodegenerative Diseases
por: Bayassi-Jakowicka, Martyna, et al.
Publicado: (2022)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity
por: Kowiański, Przemysław, et al.
Publicado: (2017)

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
por: Petrov, Dmitry, et al.
Publicado: (2017)

Postischemic Inflammation in Acute Stroke
por: Vidale, Simone, et al.
Publicado: (2017)

Neuroplasticity and Multilevel System of Connections Determine the Integrative Role of Nucleus Accumbens in the Brain Reward System
por: Bayassi-Jakowicka, Martyna, et al.
Publicado: (2021)

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
por: Trias, Emiliano, et al.
Publicado: (2016)

More about masitinib
por: Walker, Ulrich A
Publicado: (2009)

Accelerated Extracellular Nucleotide Metabolism in Brain Microvascular Endothelial Cells in Experimental Hypercholesterolemia
por: Czuba-Pakuła, Ewelina, et al.
Publicado: (2023)

Neuroprotective Effects of Guanosine in Ischemic Stroke—Small Steps towards Effective Therapy
por: Chojnowski, Karol, et al.
Publicado: (2021)

Postischemic Neuroprotection of Aminoethoxydiphenyl Borate Associates Shortening of Peri-Infarct Depolarizations
por: Fernández-Serra, Rocío, et al.
Publicado: (2022)

Interaction of Masitinib with Organic Cation Transporters
por: Harrach, Saliha, et al.
Publicado: (2022)

Transportan 10 improves the anticancer activity of cisplatin
por: Izabela, Rusiecka, et al.
Publicado: (2016)

Erratum to: Transportan 10 improves the anticancer activity of cisplatin
por: Rusiecka, Izabela, et al.
Publicado: (2016)

Masitinib Inhibits Hepatitis A Virus Replication
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2023)

Neuroprotective effects of tannic acid in the postischemic brain via direct chelation of Zn(2+)
por: Kim, Seung Woo, et al.
Publicado: (2022)

Transthyretin expression in the postischemic brain
por: Talhada, Daniela, et al.
Publicado: (2019)

The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients
por: Navarro, Jose C., et al.
Publicado: (2012)

The use of Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, in robust neuroprotection in the postischemic brain
por: Kim, Seung-Woo, et al.
Publicado: (2011)

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
por: Durojaye, Olanrewaju Ayodeji, et al.
Publicado: (2023)

MicroRNAs in Postischemic Vascular Repair
por: Caporali, Andrea, et al.
Publicado: (2012)

Correction: Transthyretin expression in the postischemic brain
por: Talhada, Daniela, et al.
Publicado: (2020)

Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
por: Milovancev, Milan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pv864ks19sbelfmafkmu4c6ngd